UBS Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

UBS Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-11,000	Closed	-$204K	–	10450
2023 Q3	$204K	Buy	+11,000	New	+$124K	﹤0.01%	5365
2016 Q1	–	Sell	-100	Closed	-$15K	–	8338
2015 Q4	$15K	Hold	100	–	–	﹤0.01%	7021
2015 Q3	$17K	Hold	100	–	–	﹤0.01%	6866
2015 Q2	$24K	Sell	100 -200	-67%	-$53.3K	﹤0.01%	6722
2015 Q1	$85K	Hold	300	–	–	﹤0.01%	5557
2014 Q4	$47K	Buy	+300	New	+$55.4K	﹤0.01%	6561

UBS Group's ICPT Position: Q4 2023 in Review

UBS Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 2,999,188 shares — an estimated $55.6M sold.

UBS Group first reported a position in ICPT in Q4 2014 and held it in 36 quarters. The position peaked at $55.6M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

UBS Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
UBS Group sold 2,999,188 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $55.6M.
UBS Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 36 quarters.
UBS Group's Intercept Pharmaceuticals, Inc. position peaked at $55.6M in Q3 2023.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.